Status:
UNKNOWN
DOTATATE PETMRI AAA Study
Lead Sponsor:
University Health Network, Toronto
Conditions:
Abdominal Aortic Aneurysm
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Abdominal Aortic Aneurysm (AAA) screening and an aging population have increased the prevalence of AAA diagnoses. Small AAAs (\<5.5cm) are monitored with ultrasound. Large AAAs may rupture and this is...
Detailed Description
The prevalence of abdominal aortic aneurysm (AAA) in those over 65 years is 4-8% and rising. Currently, AAA size is the only metric to determine risk of growth/rupture; we are unable to image the unde...
Eligibility Criteria
Inclusion
- Diagnosis of asymptomatic abdominal aortic aneurysm AAA \>3cm in maximum diameter;
- Minimum 2 years prior ultrasound or CT imaging of their AAA;
- No prior treatment for AAA;
- Age \>50 years;
- No contraindications to PET/MRI, such as claustrophobia;
Exclusion
- Pregnant females. All women of child-bearing potential must receive a negative urine pregnancy test prior to administration of 68Ga-DOTATATE;
- Allergy and/or hypersensitivity to MRI contrast agents (gadolinium) or components of 68Ga-DOTATATE drug product (as listed in IB);
- Presence of pacemaker or implanted cardioverter defibrillator (ICD);
- History of alcohol or substance abuse.
Key Trial Info
Start Date :
February 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT04811222
Start Date
February 15 2021
End Date
December 31 2023
Last Update
March 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Health Network
Toronto, Ontario, Canada, M5G 2N2